Please login to the form below

Not currently logged in
Email:
Password:

Lynparza

This page shows the latest Lynparza news and features for those working in and with pharma, biotech and healthcare.

AZ’s bet on Daiichi’s rival to Kadcyla pays off

AZ’s bet on Daiichi’s rival to Kadcyla pays off

If approved, the ADC would add to AZ’s portfolio of emerging cancer drugs, sitting alongside cancer immunotherapy Imfinzi (durvalumab), targeted therapy Tagrisso for lung cancer and PARP inhibitor Lynparza (olaparib)

Latest news

More from news
Approximately 28 fully matching, plus 45 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Virgo Health

Virgo Health is an award-winning global healthcare communications and medical education agency comprising specialists with some of the best skills,...

Latest intelligence

Webinar: Usability and UX: You’ve been asked to test...What next?
Thursday 27th June 2019 10am EDT / 3pm BST / 4pm CEST...
Event: EphMRA Annual Conference
We're sponsoring, exhibiting and presenting three papers at this year’s EphMRA Annual Conference in Warsaw, Poland....
Research Partnership and Janssen awarded runner-up in MR Excellence Awards
...

Infographics